WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation, a majority owned subsidiary of CytRx Corporation (NASDAQ: CYTR - News), announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the registration of its common stock owned by CytRx Corporation. The registration statement filed by RXi covers shares of RXi common stock that will be distributed to CytRx’s stockholders and awarded to certain directors, officers and other employees of CytRx. The registration statement also covers the resale of RXi shares to be held by CytRx after the distribution and award transactions.
